KPT-330 has antitumour activity against non-small cell lung cancer
作者： H Sun , N Hattori , W Chien , Q Sun , M Sudo
DOI: 10.1038/BJC.2014.260
关键词:
摘要: We investigated the biologic and pharmacologic activities of a chromosome region maintenance 1 (CRM1) inhibitor against human non-small cell lung cancer (NSCLC) cells both in vitro vivo. The vivo effects novel CRM1 (KPT-330) for large number anticancer parameters were evaluated using panel 11 NSCLC lines containing different key driver mutations. Mice bearing xenografts treated with KPT-330, tumour growth was assessed. KPT-330 inhibited proliferation induced cycle arrest apoptosis-related proteins lines. Moreover, combination cisplatin synergistically enhanced kill vitro. Human tumours growing immunodeficient mice markedly by KPT-330. Also, effective even transforming mutation either exon 20 EGFR, TP53, phosphatase tensin homologue, RAS or PIK3CA, suggesting drug might be variety cancers irrespective their mutation. Our results support clinical testing as therapeutic strategy NSCLC.
nature.com
readcube.com 参考文章(52)
T. T. Huang, N. Kudo, M. Yoshida, S. Miyamoto, A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes Proceedings of the National Academy of Sciences of the United States of America. ,vol. 97, pp. 1014- 1019 ,(2000) , 10.1073/PNAS.97.3.1014
Makoto Fukuda, Shiro Asano, Takahiro Nakamura, Makoto Adachi, Minoru Yoshida, Mitsuhiro Yanagida, Eisuke Nishida, None, CRM1 is responsible for intracellular transport mediated by the nuclear export signal Nature. ,vol. 390, pp. 308- 311 ,(1997) , 10.1038/36894
Deborah A. Freedman, Arnold J. Levine, Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6 Molecular and Cellular Biology. ,vol. 18, pp. 7288- 7293 ,(1998) , 10.1128/MCB.18.12.7288
Meredith S Irwin, Keiichi Kondo, Maria Carmen Marin, Lynn S Cheng, William C Hahn, William G Kaelin, Chemosensitivity linked to p73 function Cancer Cell. ,vol. 3, pp. 403- 410 ,(2003) , 10.1016/S1535-6108(03)00078-3
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham, Michael Kauffman, Alison Walker, Rebecca Klisovic, William Blum, Michael Caligiuri, Carlo M. Croce, Guido Marcucci, Ramiro Garzon, Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia Blood. ,vol. 120, pp. 1765- 1773 ,(2012) , 10.1182/BLOOD-2012-04-423160
Manuel S. Rodriguez, Jill Thompson, Ronald T. Hay, Catherine Dargemont, Nuclear Retention of IκBα Protects It from Signal-induced Degradation and Inhibits Nuclear Factor κB Transcriptional Activation Journal of Biological Chemistry. ,vol. 274, pp. 9108- 9115 ,(1999) , 10.1074/JBC.274.13.9108
Amy C Willis, Tara Pipes, Jianhui Zhu, Xinbin Chen, None, p73 can suppress the proliferation of cells that express mutant p53 Oncogene. ,vol. 22, pp. 5481- 5495 ,(2003) , 10.1038/SJ.ONC.1206505
S Al-Bahlani, M Fraser, A Y C Wong, B S Sayan, R Bergeron, G Melino, B K Tsang, P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene. ,vol. 30, pp. 4219- 4230 ,(2011) , 10.1038/ONC.2011.134
ES Newlands, GJS Rustin, MH Brampton, Phase I trial of elactocin British Journal of Cancer. ,vol. 74, pp. 648- 649 ,(1996) , 10.1038/BJC.1996.415